Abstract
Introduction
Chronic pancreatitis (CP) is defined as progressive inflammatory destruction of pancreatic secretary parenchyma with replacement by fibrous tissue, resulting generally in irreversible dysfunction of both endocrine and exocrine pancreatic function (1) (2) . CP is usually diagnosed based on clinical-historical information, results of imaging findings, pancreatic functional tests and chronically or intermittently elevated pancreatic serum enzymes (3, 4) . Serum amylase and lipase are obtained in nearly all suspected CP patients. When low serum values are obtained, does the clinician use this information to aid in CP diagnosis or is the value ignored (or perhaps considered laboratory error)?
The lipase expression can be detected to varying extent in the lingual salivary glands, gastric fundus, duodenum, liver, and the adipose tissue. But the main organ of lipase secretion is the pancreas. Total pancreatectomy patients commonly have low serum lipase levels (5, 6) . In CP, damage may affect pancreatic enzyme synthesis and entry into and clearance from the circulation.
This may result in low serum enzyme levels. In the pathologic tissue analysis, pancreatic tissue in CP demonstrates decrease of both amylase and lipase activity. Notably, amylase activity is more decreased than lipase activity (7) .
The correlation between severe exocrine insufficiency and low pancreatic juice enzyme levels is well known. Older reports note low serum pancreatic enzymes, especially lipase, in up to 50% of 7 patients with CP (8) (9) (10) (11) . Although the role of elevated serum lipase levels as a valid tool for diagnosing acute pancreatitis and acute episodes of CP has been well established, the low serum lipase levels in CP have not yet attracted much recent attention. Low serum amylase and lipase levels in CP are not discussed in several recent publications (3, (12) (13) (14) (15) (16) (17) (18) (19) . Serum amylase and lipase remain as readily available and inexpensive tests. Methodologies for pancreatic enzymes measurement reports from older literature earlier than the year 2000 are different from that used in many modern laboratories.
The aims of this study are 1. To determine if amylase and lipase levels as assessed by modern day methods are low in a portion of CP patients, 2. To compare serum pancreatic enzyme levels between CP patients and healthy controls, and 3. To evaluate whether serum pancreatic enzyme levels could be used to aid screening for CP.
Methods
Healthy volunteers were screened and prospectively enrolled in the control group. Patients who were diagnosed with calcific CP and underwent ERCP were enrolled in the patient group. Serum amylase and lipase levels were compared between the two groups. This study was approved by Indiana University Institutional Review Board prior to the commencement of the study. Serum amylase and lipase levels were compared between the two groups. If a patient had blood drawn several times during enrollment period, the lowest level among the results was used for analysis. Patients with an abnormal high serum pancreatic enzyme level before ERCP were enrolled in the study only when their levels returned to below the upper limit of normal and pain was resolved or improved after ERCP.
4) Statistical analysis
Pearson's chi square test and student t-test were used to analyze the differences between two groups. Student t-test was used to analyze the variables among the subgroups in control group.
Receiver operating characteristics (ROC) curve analysis was constructed and the area under the curve (AUC) was calculated to determine the diagnostic performance of serum pancreatic enzymes.
The level of variables were described as mean ± standard deviation (S.D.). P<0.05 was considered 
Results
A total of 180 healthy volunteers were screened and enrolled in the control group. Ten healthy volunteers were excluded due to abnormal high levels of pancreatic enzymes (5.6%), resulting in a total of 170 healthy volunteers finally enrolled in the control group (44 men, 126 women with a mean age of 48.1 years; range, 20-78 years). A total of 220 patients were identified with calcific CP and underwent 370 ERCP procedures, of which 70 patients were excluded: 33 patients with persistent elevations of pancreatic serum enzyme levels; 11 patients with history of other gastrointestinal disease or previous gastrointestinal operation; 9 patients with age <18 or >79; 9 patients with inadequate information; 5 patients with chronic kidney disease; 3 patients with neoplastic disease. A total of 150 patients (76 men, 74 women with a mean age of 54.0 years; range, 23-78 years) were enrolled in the patient group (Fig. 1) .
The characteristics of the study participants are presented in Table 2 . There were significant differences in mean age (mean values ± S.D.; 48.1 ± 15.9 vs. 54.0 ± 12.2, respectively, p<0.001) and sex ratio (male : female; 44 : 126 vs. 76 : 74, respectively, p<0.001) between control group and patient group due to differences of frequency of volunteer subgroups. The mean serum amylase level was significantly higher in the control group compared with that of the patient 11 group (normal range, 19-86 U/L: 48.1 ± 13.2 U/L vs. 34.8 ± 17.2 U/L, respectively, p<0.001). The mean lipase level was also significantly higher in the control group compared with that of the patient group (normal range, 7-59 U/L: 26.4 ± 11.3 U/L vs. 16.3 ± 11.2 U/L, respectively, p<0.001) (Fig. 2) .
Because of non-equal distribution of sex and age in the volunteer group, subgroup analyses were done in the control for the evaluation of age-related and sex-related differences. Between younger-age (age 18-49) and older-age (age 50-79) subgroups, there was no significant difference of serum amylase and lipase levels (amylase: 46.9 ± 11.6 U/L vs. 45.0 ± 11.4 U/L, respectively, p=0.326; lipase: 24.1 ± 10.1 U/L vs. 25.9 ± 10.7, respectively, p=0.303). Between male and female subgroups, there was no significant difference of serum amylase and lipase levels (amylase: 46.5 ± 14.2 U/L vs. 48.7 ± 12.8 U/L, respectively, p=0.362; lipase: 29.6 ± 13.5 U/L vs. 25.3 ± 10.2 U/L, respectively, p=0.058) (Table 3) .
Interestingly, no one in the healthy volunteer group had values of serum amylase and lipase levels below the reference range (normal range). Using mean value minus 2 S.D. of control group, 45 patients (30%) had low amylase level (mean level, 16.5 ± 4.7 U/L), 28 patients (18.7%) had low lipase level (mean level, 3.1 ± 0.4 U/L), 16 patients (10.7%) had both levels low and 57 patients (38.0%) had either of both levels low.
We next generated the receiver operation characteristic (ROC) curves to assess the potential usefulness of low serum pancreatic enzyme levels as diagnostic modalities for CP (Fig. 3 and Table   4 ). On the ROC curve analysis for amylase level, AUC was 0.740 (95% confidence interval), and sensitivity and specificity were 70.0% and 70.6%, respectively, with an optimum diagnostic cut-off value of 41.5 U/L. Specificity of serum amylase level for diagnosis of CP was 94.1% with a cut-off value of 27.5 U/L. On the ROC curve analysis for lipase level, AUC was 0.748 (95% confidence interval), and sensitivity and specificity were 69.3% and 68.8%, respectively, with an optimum diagnostic cut-off value of 19.5 U/L (Fig. 3 and Table 3 Our results show that patients with established calcific CP (with obviously advanced disease) had significantly lower levels of serum pancreatic enzymes than healthy control group. Furthermore, when compared to healthy control group, 57 patients (38%) out of 150 patients had at least 1 enzyme level more than 2 S.D. below the levels of control group. These results suggest that low levels in routine pancreatic serum enzyme tests should not be deemed "normal" nor dismissed clinically unimportant.
Low serum lipase and amylase levels in CP were observed long ago (8) (9) (10) (11) . Could this observation apply to currently used laboratory methodology? This study confirms prior studies and emphasizes the diagnostic values of low serum pancreatic enzymes. We conducted an ROC curve analysis to determine the diagnostic possibility of detecting patients with a CP. As can be seen in Fig. 3 and Table 4 , the AUC for serum amylase level and serum lipase level were both greater than 0.7, with sensitivity and specificity ranging between 65% and 70% depending on the optimal cutoff value. These values were somewhat different from the values presented by the diagnostic modalities of CP, but the specificity increased rapidly to beyond 90% with lower cut-off values.
Specificity of serum amylase was 94.1% with cut-off level of 27.5 U/L and 100% when the level was lower than 18.5 U/L. Specificity of serum lipase was 95.9% when the cut-off level was 10.5 U/L and 100% when the cut-off level was lower than 7.5 U/L. These results suggest that normal 14 subjects do not show values below a certain level and that this cut-off may be useful for the diagnosis of CP. The clinician should not ignore low serum amylase and lipase levels as they suggest chronic pancreatitis in absence of pancreas resection surgery.
Previously reported noninvasive or indirect laboratory tests have highly variable accuracy in suggesting a diagnosis of CP depending on the severity of the disease (18, 19) . Serum trypsin level has similarily been found to be low in up to 50% of calcific CP patients and moderate sensitivity in late disease state with steatorrhea. Some reports mentioned this in discussion of chronic pancreatitis, while the sensitivity is at least intermediate, the specificity is near 100% (10, 18, 19) . This would appear to have equal diagnostic values for amylase and lipase low values. The serum trypsin assay has not replaced amylase and lipase in clinical practice due to requiring several days to obtain a result, and two-fourfold more expensive than serum amylase and lipase levels in our hospital. A large-scale, prospective, follow-up study based on our results would be able to establish critical diagnostic basis, such as using serum pancreatic enzyme level as an economic, long-term followup in patients with symptoms of CP but unremarkable findings from routine tests. If a patient's levels are below certain levels or continuously decreasing, more accurate diagnostic tests can be recommended more confidently for confirmation of CP. Our study was not designed to detect the difference in pancreatic enzyme levels depending on the severity of CP or in the course of disease progression from recurrent pancreatitis to chronic calcific pancreatitis in a long-term follow-up.
These could be addressed in future studies.
Limitations of our study are as follows. Healthy volunteers were enrolled prospectively but the subjects in the patient group were enrolled retrospectively. Although there is no statistical difference of serum amylase and lipase level between male and female subgroup, men and women were not evenly distributed across the healthy group due to low rate of volunteering in males, especially younger males. Patients with early-stage CP were not involved in this comparative study, and those differences in terms of the severity or cause of CP could not be investigated. We are not aware of other clinical conditions with low serum amylase and lipase level (except for resection surgery of pancreas or salivary glands, chronic salivary gland disease, or pancreatitis with extensive necrosis, etc.).
In conclusion, our results suggest that low serum amylase and lipase levels should not be discarded for patients, and that further testing may be warranted if there is the possibility of 16 underlying pancreatic disease. Also, low serum amylase and lipase levels as detected by modern methodology laboratory can be used to aid in the screening of CP. These results confirm previous studies stating up to 50% sensitivity for CP diagnosis. Further studies in non-calcific chronic pancreatitis are needed to clarify the pancreatic enzyme levels in regards to the demographic factors and severity status of chronic pancreatitis. 
